Work

Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway

Year: 2016
Type: article
Abstract: // Sheng-Fan Wang 1, 2 , Meng-Shian Chen 1 , Yueh-Ching Chou 1, 2, 3 , Yune-Fang Ueng 1, 4, 5 , Pen-Hui Yin 6 , Tien-Shun Yeh 7 , Hsin-Chen Lee 1 1 Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan 2 Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan 3 School of Pharmacy, Taipei Medical University, Taipei, Taiwan 4 National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan 5 Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan 6 Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan 7 Institute of Anatomy and Cell Biology, School of Medicine, National Yang-Ming University, Taipei, Taiwan Correspondence to: Hsin-Chen Lee, email: [email protected] Keywords: gastric cancer, mitochondrial dysfunction, cisplatin resistance, xCT, retrograde signaling Received: June 14, 2016 Accepted: September 21, 2016 Published: September 30, 2016 ABSTRACT Mitochondrial DNA mutations and defects in mitochondrial enzymes have been identified in gastric cancers, and they might contribute to cancer progression. In previous studies, mitochondrial dysfunction was induced by oligomycin-enhanced chemoresistance to cisplatin. Herein, we dissected the regulatory mechanism for mitochondrial dysfunction-enhanced cisplatin resistance in human gastric cancer cells. Repeated cisplatin treatment-induced cisplatin-resistant cells exhibited high SLC7A11 (xCT) expression, and xCT inhibitors (sulfasalazine or erastin), xCT siRNA, or a GSH synthesis inhibitor (buthionine sulphoximine, BSO) could sensitize these cells to cisplatin. Clinically, the high expression of xCT was associated with a poorer prognosis for gastric cancer patients under adjuvant chemotherapy. Moreover, we found that mitochondrial dysfunction enhanced cisplatin resistance and up-regulated xCT expression, as well as intracellular glutathione (GSH). The xCT inhibitors, siRNA against xCT or BSO decreased mitochondrial dysfunction-enhanced cisplatin resistance. We further demonstrated that the upregulation of the eIF2α-ATF4 pathway contributed to mitochondrial dysfunction-induced xCT expression, and activated eIF2α kinase GCN2, but not PERK, stimulated the eIF2α-ATF4-xCT pathway in response to mitochondrial dysfunction-increased reactive oxygen species (ROS) levels. In conclusion, our results suggested that the ROS-activated GCN2-eIF2α-ATF4-xCT pathway might contribute to mitochondrial dysfunction-enhanced cisplatin resistance and could be a potential target for gastric cancer therapy.
Source: Oncotarget
Language: English
Open Access status: diamond
OpenAlex ID: W2525112160
FWCI: 2.415
Cites: 52
Cited by: 111
Related to: 10